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Abstract
Background: The lung is the second most common site for metastatic malignant melanoma, with a poor
prognosis. In this regard, identify clinicopathological predictors for Melanoma Lung Metastases (MLM) plays a
pivotal role in clinical practice.
Methods: We computer-searched the clinical records of all our patients registered in our melanoma database to
identify patients that presented MLM. Kaplan-Meier product was used to estimate time to MELANOMA LUNG
METASTASES (TMLM) and Overall Survival (OS); while the log-rank test was used to evaluate differences between
the survival curves. Cox proportional hazards regression was performed in the analysis between clinicopathological
features of the primary tumor and MLM.
Results: A total of 63 patients with MLM were included in our analysis. Median TMLM was 27.4 months, while
median OS was 55.5 months, with a Median Lung Metastases Survival (MLMS) of 10 months. Melanoma patients
with a primary axial tumor (p<0.001) and with an age ≤ 60 years (p=0.01) showed a better TMLM. While OS was
statistically significant higher only in axial melanomas (p<0.001), multivariate analysis showed that peripheral site of
the primary tumor remained the main predictor to develop MLM, with a significant influence in TMLM and also in the
long-term (p<0.01 and p=0.04).
Conclusions: Currently no standardized therapies exist for MLM. In this regard, the prevention of secondary
recurrences plays a pivotal role in the management of melanoma patients. According to our results, peripheral
melanoma is the main predictor for development of MLM.
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Introduction
The lungs are the second most frequent site of metastases from
extra thoracic malignancies, while 20% of metastatic diseases is
isolated to the lungs [1]. At the same time, they are the second most
common site for metastatic malignant melanoma, with a one-year
survival rate of 53% [1].
Metastasectomy remains the primary treatment for Melanoma
Lung Metastases (MLM) with ≤ 2 nodules and chemotherapy is
principally used in those with multiple metastases. Several
chemotherapeutic drugs are available, including dacarbazine, cisplatin,
carmusine (also in combination with various immunotherapies),
BOLD-regimen+G-CSF, ipilimumab, nivolumab, vemurafenib and the
association between dabrafenib and trametenib.
However, although different authors have identified clinical
variables present at time of MLM diagnosis as predictive of post-MLM
survival, relatively few studies have been conducted to identify patients
with increased risk of developing MLM, basing on the characteristics
of the primary tumour. In this regard, factors such as site of primary
tumour, Breslow thickness, ulceration, and Sentinel Lymph Node
(SLN) can play an important role as predictors for a secondary
pulmonary localization and for a relative better management of the
patient.
We conducted a study of our patients with MLM, in order to
identify risk factors useful to predict the development of MLM and to
evaluate the impact of the clinicopathological features of the primary
tumour on time to Melanoma Lung Metastases (TMLM) and Overall
Survival (OS).
Material and Methods
We computer-searched the clinical records of all our patients
registered in our melanoma database from June 1998 to June 2013, to
identify patients that presented or developed Melanoma Lung
Metastases (MLM).
Clinical and pathological data were obtained from the electronic
database. The following parameters were registered: demographics,
anatomical localization and histological characteristics of primary
melanoma, time interval between diagnosis of primary melanoma and
first recurrence, time interval between diagnosis of primary melanoma
and MLM, localization of other visceral metastases and date of death
and/or last follow-up.
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The diagnosis of MLM was usually obtained by chest radiography,
computed tomography and thoracothamy. If possible a histological
examination was performed. MLM diagnosed within 30 days of
diagnosis of the primary melanoma were considered as synchronous.
We followed all patients from the date of the first visit to date of
death or last follow-up. Patients underwent regular follow-up in our
Department with periodical exams and instrumental assessment
through radiography, sonography, CT, MRI, bone scintigraphy and
PET.
To establish risk factors we analyzed the following parameters: sex
(female or male), age (≤ 60 or ≥ 61 years), anatomic site of primary
tumor (axial or peripheral), Breslow thickness (≤ 1.0 mm or ≥ 1.01
mm), and ulceration (presence or absence), and sentinel lymph node
biopsy (positive or negative). For anatomic sites of primary tumor,
axial site included head, neck and trunk, while peripheral sites
included upper and lower limbs. These parameters are the same used
by Balch et al. to establish AJCC melanoma staging 7th edition [2].
Statistical analysis
The Incidence Rate (IR) was calculated as the ratio between the
observed patients with MLM and all melanoma patients founded in
our electronic database. Then we analyzed the following parameters:
Melanoma Lung Metastases Survival (MLMS), Disease Free Survival
(DFS), time to Melanoma Lung Metastases (TMLM) and Overall
Survival (OS). DFS was calculated from diagnosis of primary tumor to
first recurrence, while TMLM from melanoma diagnosis to MLM.
Assuming that the effects of the predictor variables are constant over
time, we used Cox proportional hazards regression between MLM and
the characteristics of disease at the time of first diagnosis. MLMS was
calculated from diagnosis of MLM to death and/or last follow-up,
while OS was calculated from first melanoma diagnosis to death
and/or last follow-up. Kaplan-Meier product was used to estimate
curves for TMLM and OS, and the log-rank test was used to evaluate
differences between the survival curves. Patients who were lost to
follow-up or who were alive at the time of last follow-up were censored
at the date of their last follow-up. A p value < 0.05 was considered
statistically significant.
Results
A total of 63 patients were included in the analysis. They were 21
female (33%) and 42 male (67%), with an IR equal to 1:29 melanoma
patients present in our melanoma database. The methods of diagnosis
were chest radiography (n=27), computed tomography (n=25) and
thoracotomy (n=11). The median age at time of lung metastases was of
55.5 years (ranging 22-78 years). Twenty-four were ≥ 61 years while 39
were ≤ 60 years (Table 1).
Regarding the first diagnosis, 59 patients showed a primary
cutaneous melanoma and 1 patient a mucosal melanoma. The
anatomic site of the primary tumor was axial in 40 patients and
peripheral in 19 patients. The Sentinel Lymph Node (SNL) biopsy was
positive in 10 patients and negative in 50 patients; two patients
presented an occult nodal melanoma while 1 patient a primary
melanoma of the lung (melanoma with unknown primary).
The Breslow thickness was ≥ 1.01 mm in 52 patients (88%), with a
median thickness of 3.75 mm (ranging 1.01 mm-18 mm); while it was
≤ 1.0 mm only in 7 patients (12%) with a median thickness of 0.65 mm
(ranging 0.6 mm- 0.9 mm). In one patient with mucosal melanoma,
Breslow thickness was not evaluated. The ulceration of the primary
tumor was present in 18 patients (30.5%) (Table 1).
 Number (n) Percentage (%)
Gender   
Male 42 67
Female 21 33
Age   
≤60 (17 M : 22 F) 39 62
≥60 (20 M : 4 F) 24 38
Cutaneous Sites*   
Peripheral 19 32
Axial 40 68
Breslow*   
≤1.00 mm 52 88
≥1.1 mm 7 12
Ulceration*   
Presence 18 30
Absence 41 70
SLN**   
Positive 10 17
Negative 50 83
* excluding melanoma with unknown primary and mucosal melanoma;
** excluding melanoma with unknown primary.
Table 1: Baseline and primary tumour characteristics of melanoma
patients who developed lung metastases
At the time of melanoma lung metastases (MLM) diagnosis, 26
patients (41%) presented also other secondary visceral lesions, while
the remaining 39 patients presented no other visceral involvement.
The extra pulmonary sites of metastases were nodal (64%) cutaneous
and subcutaneous tissues (20%), bone (4%), ovary (4%) and brain
(8%). At the time of MLM diagnosis, six patients showed ≤ 2
metastatic nodules, while the remaining patients showed ≥ 3
metastatic nodules.
After MLM, 60% patients were treated with chemotherapy, while
five died before starting any treatment. Among treated patients, 12
patients performed a surgical pulmonary resection, while the
remaining patients preformed only medical treatments. Regarding
medical treatments, patients were treated with the following regimens:
dacarbazine, BOLD + G-CSF regimen, ipilimumab and vemurafenib
(for patients with B-RAF mutation). BOLD + G-CSF regimen included
bleomycin at 15 mg intravenously on day 1 and 4, Oncovin (or
Vincristine) at 1 mg/m2 intravenously on day 1 and 5, lomustine at 80
mg/m2 on day 1 and dacarbazine at 200 mg/m2 intravenously on day 1
through 5, while in the intervals recombinant human G-CSF at the
dosage of 5 µg/kg/day was administered sub cutis three times a week
for 6 weeks.
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The analysis of melanoma Lung Metastases Survival (MLMS) has
resulted in a median MLMS of 10 months (range 1 - 89 months).
Median Disease Free Survival (DFS) was 23 months, while median
time to Melanoma Lung Metastases (TMLM) was equal to 27.4
months. Specifically, patients with a Breslow thickness ≥ 1.01 mm
showed a median TMLM of 24 months, while for patients with
Breslow thickness less than ≤ 1.0 mm the median TMLM was 48
months (p=0.4). For patients without ulceration TMLM was equal to
47 months, while for patients with ulceration was 23 months (p=0.8).
Patients with axial primary sites showed a TMLM of 43 months while
for those with peripheral sites it was 7 months (p<0.001) (Figure 1a).
Patients with an age ≥ 61 years showed a TMLM of 25 months, while
patients ≤ 60 years had a TMLM of 30 months (p=0.01) (Figure 1b).
Finally a better behavior was observed for female patients, with a
TMLM of 31 months compared to male patients (p=0.05).
Figure 1a: Kaplan-Meier curves of Time to Melanoma Lung
Metastases (TMLM) according to anatomical site of the primary
tumor (axial or peripheral)
Figure 1b: Kaplan-Meier curves of Time to Melanoma Lung
Metastases (TMLM) according to age (≤ 60 or ≥ 61 years)
Performing Cox proportional hazards regression between the single
variables and TMLM, we found that anatomical site of the primary










Gender       
Male 23 0.05 0.7 50 0.4 0.5
Female 31   83   
Age       
≥61 25 0.01 0.2 35 0.2 0.4
≤60 30   83   
Sites       
Axial 43 <0.001 <0.01 87 <0.001 0.04
Peripheral 7   20   
Ulceration       
Presence 23 0.8 0.3 68 0.3 0.3
Absence 47   46   
Breslow       
≥ 1.01 mm 24 0.4 0.5 54 0.9 0.9
≤ 1.00 mm 48   61   
SLN       
Positive 29 0.3 0.9 35 0.07 0.08
Negative 19   61   
pa Kaplan-Meier product and log-rank test between TMLM curves; pb Cox
proportional hazards-regression between TMLM and predictive factors
analyzed;
pc Kaplan-Meier product and log-rank test between OS curves;
pd Cox proportional hazards-regression between OS and predictors analyzed;
n indicates number of patients;
SLN indicates sentinel lymph node.
Table 2: Time to melanoma lung metastases (TMLM), overall survival
(OS) and clinicopathological features in melanoma lung metastates
OS of the entire cohort of patients with MLM, after primary
melanoma diagnosis, was 55.5 months (range 1.3-189 months). We
analyzed OS of MM patients with MLM using Kaplan-Meier product
according to data previously described: gender, age, sites of primary
tumor, Breslow thickness, ulceration and SLN. Patients with negative
SLN, without ulceration, with a Breslow thickness ≤ 1.00 mm, and
female patients showed a better OS; however only axial site reached a
statistical significance (p<0.04) (Figure 2). Also in the long-term, at
Cox proportional hazards regression, anatomical site remained the
main predictor (p=0.04) (Table 2).
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Figure 2: Kaplan-Meier curves of overall survival (OS) of melanoma
lung metastases (MLM) according to anatomical site of the primary
tumor ( axial or peripheral)
Discussion
According to 2009 American Joint Cancer Committee Staging
Melanoma Database, patients with melanoma lung metastases (MLM)
are classified as IV M1b, with a 1-year survival rate of 51% [2]. In
literature, there are several reports about surgical approaches to MLM,
while there are few data regarding clinicopathological predictors to
develop MLM. Like Balch et al. [3], we included in the current report
patients who performed pulmonary metastasectomy as well as patients
who were not considerated to be surgical candidates. To date,
metastasectomy remains the primary treatment for lung metastases
with ≤ 2 nodules, while anti-CTL4 antibody (ipilimumab), anti-PD1
antibody (nivolumab), vemurafenib and the association between
dabrafenib and trametenib (for B-RAF mutations), are the most recent
chemotherapy treatments, which have shown an excellent
therapeutical response in this class of patients. However, the aim of
our study was not to evaluate the surgical and/or the medical approach
to MLM, but rather to evaluate the predictors of the primary tumor to
develop MLM.
Reviewing the literature and analyzing 1.105 MLM patients from 8
different reports, we found that, after a complete resection of MLM,
the median melanoma lung metastases survival (MLMS) was equal to
25 months, compared to a median of 11 months in the unresectable
ones [4-11]. Our general MLMS was of 10 months, approaching the
data usually reported regarding unresectable and multiple MLM [4].
In fact, probably, the high percentage of multiple MLM in the current
report could explain the low median MLMS found in our analysis. In
this regard, the importance of the number of MLM has been
emphasized by many authors, with a high survival rate for patients
with ≤ 2 lesions [4-12].
Also regarding TMLM, we found a median TMLM comparable
with the one previously reported [6]. In this regard, according to our
results and to the literature, the fact that median TMLM of all MLM
occurred before 4 years, highlights the importance of a strict follow-up
in the early time period, following the diagnosis of the primary
melanoma, in order to reduce the risk of pulmonary recurrences, and
to improve and extend TMLM.
As reported in literature, in our study the lung represented the first
metastatic site in the majority of patients (62%). Besides, regarding
patients who performed a sentinel lymph node biopsy (SLN),
excluding melanoma with unknown primary, only 17% of patients
presented a positive SLN, while the remaining were all negative, and in
two patients SLN was not performed because not provided (pTIA,
AJCC stage IA). In fact, in a previous report, analyzing 292 patients
with MLM, only 36 patients (12.3%) had positive nodes [5]. The high
percentage of extra-nodal region as first metastatic sites and the low
percentage of nodal involvement in MLM patients show that the
conventional metastatic nodal dissemination [12] has not followed.
This percentage may indicate that the number of skip metastases in
this class of patients is higher than the average percentage detected in
general melanoma population , where skip metastases account to ≤ 1%
[13]. Up to now, the influence of lymph nodal involvement at the time
of MLM remains unclear and require further investigations [5,7].
Regarding the first anatomical site, it is known that many of the
preferences observed for the spread of specific cancers to specific
metastatic locations can be explained by the direction of blood flow. In
this regard, organs in close proximity are likely to be the main sites of
metastases for a particular primary tumor. While, generally, malignant
melanoma is usually considered as different from other solid tumors,
because it is a cutaneous malignancy with straightforward lymphatic
flow, which can be mapped [7]. However (as reported above) about
one-third of the locations of frequent metastases is puzzling about this
observation. In our sample, although 68% of patients showed an axial
primary tumor, TMLM (p<0.001) and OS (p<0.001) were both worse
for those arisen in the peripheral sites. At the Cox proportional
hazards-regression, anatomical site remained the main predictor.
Conversely the literature, where ulceration is a marker of an
increased risk of hematologic dissemination, extracellular matrix
invasion and subsequent development of distant metastases
(independently of tumor thickness), ulceration did not remain a
predictor in the statistical analysis, as observed in case of melanoma
brain metastases (although we found a worse TMLM and OS for
ulcerated melanoma) [14,15]. These results, in contrast with Reintgen
et al. [13], highlight that probably the route of lung metastatization in
MLM does not follow the conventional pathophysiological processes
involved and widely known for melanoma. This observation is
confirmed also by the low percentage of nodal involvement in our
sample. In this regard, the presence of a malignant melanoma of the
peripheral sites is associated with a higher risk of MLM than the ones
arose in the axial sites, regardless of the other clinicopathological
aspects.
Despite the advent of new therapeutic treatments, mortality rate
due to melanoma continues to rise at an alarming rate. Our report
suggested that after the surgical removing of the primary tumor (also
in absence of metastatic recurrences), according to clinicopathologic
predictors, it may be selected a class of melanoma patients with an
increased risk of MLM, in order to perform a close clinical and
instrumental follow-up and/or to perform a tertiary chemoprevention
(identifying target patients who have had previous melanoma, in order
to prevent development of secondary recurrences), since currently
there are no approved adjuvants therapies for this malignancy. In this
regard, the prevention of secondary recurrences (especially in
melanoma-target organs, such as lungs) plays a pivotal role in the
management of melanoma. Therefore, identify target patients in order
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to avoid “target organ recurrences” (as MLM) remains a crucial point
in the management of malignant melanoma, as well as for the other
malignancies.
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